Post-transcriptional microRNA repression of PMP22 dose in severe Charcot-Marie-Tooth disease type 1

Area of Science:

• Genetics
• Molecular Biology
• Neuroscience

Background:

• Charcot-Marie-Tooth disease type 1A (CMT1A) is a common inherited neuropathy caused by PMP22 gene duplication.
• MicroRNAs regulate gene expression post-transcriptionally, with miR-29a shown to reduce PMP22 levels in rodent models.

Purpose of the Study:

• To investigate the role of microRNA repression in a human CNV-associated neuropathy.
• To examine the impact of a PMP22 3'-UTR deletion on gene expression and disease phenotype.

Main Methods:

• Analysis of a novel de novo deletion in the PMP22 3'-UTR in a patient with severe neuropathy.
• Transcript analysis of dermal myelinated nerve fibers to quantify PMP22 levels.
• Reporter assays in Schwann cell lines with wild-type and mutant PMP22 3'-UTRs, with and without miR-29a mimic overexpression.

Main Results:

• The deletion in the PMP22 3'-UTR was predicted to disrupt the miR-29a binding site.
• Increased PMP22 transcript levels were observed in patient nerve fibers.
• Reporter assays showed increased activity with the mutant 3'-UTR, unaffected by miR-29a mimic, confirming miR-29a's regulatory role.

Conclusions:

• This study provides the first human evidence of 3'-UTR-mediated microRNA repression affecting gene expression in a CNV-associated phenotype.
• The findings highlight miR-29a's critical role in regulating PMP22 expression.
• The results suggest potential therapeutic strategies targeting miR-29a for CMT1A and related neuropathies.